Efficiency of four solutions in removing 23 conventional antineoplastic drugs from contaminated surfaces

Nicolas Simon, Nicolas Guichard, Pascal Odou, Bertrand Decaudin, Pascal Bonnabry, Sandrine Fleury-Souverain

1 Pharmacy, Geneva University Hospitals and Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland, 2 Univ. Lille, CHU Lille, ULR 7365 –GRITA–Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France

* nicolas.simon@univ-lille.fr

Abstract

Background

Residual contamination by intravenous conventional antineoplastic drugs (ICAD) is still a daily issue in hospital facilities. This study aimed to compare the efficiency (Eff Q) of 4 different solutions to remove 23 widely used ICADs from surfaces.

Method and findings

A solution containing 23 ICADs (4 alkylating agents, 8 antimetabolites, 2 topo-I inhibitors, 6 topo-II inhibitors and 3 spindle poisons) was spread over 100 cm² stainless steel. After drying, decontamination was carried out using 10 × 10 cm wipes moistened with 300 μL of one of the following solutions: 70% isopropanol (S1); ethanol-hydrogen peroxide 91.6–50.0 mg/g (S2); 10⁻² M sodium dodecyl sulphate/isopropanol 80/20 (S3) or 0.5% sodium hypochlorite (S4). Six tests were performed for each decontamination solution. Two modalities were tested: a single wipe motion from top to bottom or vigorous wiping (n = 6 for each modality).

Residual contamination was measured with a validated liquid chromatography with tandem mass spectrometry detection method. Solution efficiency (in %) was computed as follows:

\[ \text{Eff}_{Q} = 1 - \left( \frac{\text{quantity after decontamination}}{\text{quantity before decontamination}} \right) \]

\[ \text{as median (min–max) for the 23 ICADs. The overall decontamination efficiency (Eff}_{Q}\) of the 4 solutions was compared by a Kruskall-Wallis test. Decontamination modalities were compared for each solution and per ICAD with a Mann-Whitney test (p<0.05).

Eff Q were significantly different from one solution to the next for single wipe motion decontamination: 79.9% (69.3–100), 86.5% (13.0–100), 85.4% (56.5–100) and 100% (52.9–100) for S1, S2, S3 and S4 (p<0.0001), respectively. Differences were also significant for vigorous decontamination: Eff Q of 84.3% (66.0–100), 92.3% (68.7–100), 99.6% (84.8–100) and 100% (82.9–100) for S1, S2, S3 and S4, respectively (p<0.0001). Generally, vigorous decontamination increased Eff Q for all tested solutions and more significantly for the surfactant.
Conclusion

Decontamination efficiency depended on the solution used but also on the application modality. An SDS admixture seems to be a good alternative to sodium hypochlorite, notably after vigorous chemical decontamination with no hazard either to materials or workers.

Introduction

Occupational exposure to intravenous conventional antineoplastic drugs (ICADs) is a daily problem widely encountered in care settings. Traces of contamination have been found in many sectors of the drug supply chain, from industry [1] to hospitals [2,3] and to patients’ homes [4]. More recently, veterinary clinics have also been found liable to occupational exposure [5].

Since the first report [6], numerous articles have highlighted different risks, varying according to the case. For example, sudden massive contamination (e.g. vial breaking) may cause acute symptomatology [7–9], which is an uncommon event. Chronic exposure could lead to clinical or biological disorders, notably reproductive risks or cytogenetic effects [10,11].

Rapidly, professional recommendations were published [12–14], followed by institutional recommendations [15–21]. All these recommendations insist on the need to combine several protective measures. Indeed, personal protective equipments (e.g. gloves, gowns, mask...) are recommended to avoid a direct contact between the operator and the chemical hazard. Such equipments have to be combined to collective equipments (e.g. compounding isolators or laminar air-flow hoods, specific sterile medical devices for preparation or administration...) which are devoted to decrease the widepreading of the chemical contamination to the surrounding [19,21,22,23]. Nonetheless, the respect for these recommendations is not absolute and appears to differ among healthcare professionals [24]. Moreover, the use of protective tools varies according to healthcare facilities. Consequently, healthcare workers are exposed to varying levels and types of contamination.

One safety measure which must be developed is the elimination of contaminants from workplaces. This was recently mentioned in the <USP800> monograph and in the latest recommendations of the American Society of Healthcare-system Pharmacists [23,25]. Removing contamination from surfaces has been studied for more than thirty years. A recent review of the literature discussed all the decontamination strategies studied and published [26] and in what conditions: contaminants used, contamination level, surface type and operating procedure [26]. According to the <USP800>, contaminants may be removed from surfaces either by deactivation, that is to say by chemical degradation, or by decontamination, involving a physical process (i.e. desorption). Desorption strategies were studied on different antineoplastic drugs after intentional surface contamination. Some studies focused on 1 or 2 drugs [27–32], testing solutions of different natures (quaternary ammonium, biguanide, alcohol-based solutions). Others were performed on 10 drugs with a wider range of solutions (organic solvent; anionic, non-ionic or cationic surfactants; oxidant or water) [33]. Considering the different physicochemical properties of ICADs, some strategies were found to be of little efficacy (e.g. 70% isopropanol). Nonetheless, certain approaches were promising such as diluted oxidant (e.g. sodium hypochlorite) or the combination of a surfactant agent and an alcoholic solvent (e.g. sodium dodecyl sulfate/isopropanol). Even if these studies were tested on 10 compounds and have yielded interesting results, they concern only a small number of the...
antineoplastic drugs handled in hospital. Therefore, efficacy on numerous other drugs from
different antineoplastic drug families requires evaluating.

The objective of this in vitro study was to assess the efficiency of four different solutions
after intentional contamination on stainless steel surfaces. The originality of this study lies in
the assessment of decontamination solutions and application modalities on 23 conventional
antineoplastic drugs from all conventional antineoplastic drug families.

Materials and methods

Chemicals

The ICADs used for experiments were: 5-fluorouracil (batch# PE4SH-RM), methotrexate
(batch# G07UG-01) and dacarbazine (batch# Z3J8O-SF), purchased from Tokyo Chemical
Industry (Zwijndrecht, Belgium); gemcitabine (batch# A0375170), purchased from Acros
Organic (Geel, Belgium); busulfan (batch# BCBN8120V), purchased from Sigma-Aldrich
(Buchs, Switzerland); ganciclovir, purchased from Roche Pharma (Cymeve ne®, batch#
B4091B08, Reinach, Switzerland); cytarabine (batch# 3-YFD-59-1), epirubicin (batch# 11-
CGS-118-1) and topotecan (batch# 8-MSW-162-1) purchased from Toronto Research
Chemicals (North York, ON, Canada); raltitrexed (batch# MG10453-29102016), pemetrexed
(batch# AGN2017-685), docetaxel (batch# CS13527-18112016), paclitaxel (batch# CS22539-
20112016), vincristine sulfate (batch# MC-10452-0212016), doxorubicin hydrochloride
(batch# MC10454-0612016), daunorubicin (batch# MC10456-1712016), idarubicin (batch# 5-
CGS-96-1), etoposide (batch# MC10457-20102016), etoposide phosphate (batch#
MC305547-21082017), irinotecan hydrochloride (batch# MC20783-21082017) and fludara-
bine phosphate (batch# MC444607-21082017) brought from Toronto Research Chemicals (North York, ON, Canada); cyclophosphamide (batch# MC305547-21082017), daunorubicin (batch# MC10456-1712016), idarubicin (batch# 5-
CGS-96-1), etoposide (batch# MC10457-20102016), etoposide phosphate (batch#
MC305547-21082017), irinotecan hydrochloride (batch# MC20783-21082017) and fludara-
bine phosphate (batch# MC444607-21082017) brought from Pharmaserv (Sanzstad, Switzer-
land). Cyclophosphamide (batch# 7F124) and ifosfamide (batch# 7H025) were obtained from
Baxter EG (Endoxan® and Holoxan®, respectively, Opfikon, Switzerland). Internal standards
(IS) for the analytical assay ([13C]-fluorouracil, batch# JA-ALS-16-130P3; [13C]-methotrexate,
batch# TM-ALS-12-134-B1; [13C6]-irinotecan, batch# TM-ALS-12-257-P1; [3H8]-
cyclophosphamide, batch# LSG-ALS-12-017-P1; and [3H6]-paclitaxel, batch# TF-ALS-11-
066-P1) were purchased from Alsachim (Strasbourg, France).

All solvents were mass spectrometry grade and all chemicals were obtained in the highest
available analytical quality. Dimethylsulfoxide (DMSO) was purchased from Sigma-Aldrich
(Buchs, Switzerland). Ammonium hydroxide, acetic acid and acetonitrile were obtained from
Merck (Darmstadt, Germany). Ultrapure water (UPW) was obtained from a Milli-Q purifica-
tion system from Millipore (Bedford, MA, USA).

Preparation of working solutions

Standard stock solutions were prepared by diluting standard compounds in DMSO or UPW
for pemetrexed at a concentration of 1 mg/mL and were stored at -80°C. One stock solution
was prepared with:

- Group A (C_A = 10,000 ng/mL for each compound) comprised of 5-fluorouracil, busulfan,
cyclophosphamide, cytarabine, dacarbazine, docetaxel, etoposide, etoposide phosphate, ganc-
iclovir, gemcitabine, idarubicin, ifosfamide, methotrexate, paclitaxel, pemetrexed and
raltitrexed;
- Group B (C_B = 50,000 ng/ml for each compound) comprised of daunorubicin, doxorubicin,
epirubicin, topotecan and vincristine;
- Group C comprised of only fludarabine at a concentration of C_C = 100,000 ng/mL.
Internal standard stock solutions were prepared by diluting individual radiolabelled IS in DMSO at 0.1 mg/mL and also stored at -80˚C.

**Contamination of surfaces**

Contamination was carried out with 50 μL of a 1/50th dilution of the stock solution. Thus, the intentional contaminations were 200 ng, 1,000 ng and 2,000 ng for groups A, B and C, respectively.

The 50 μL was randomly dropped on a 10×10 cm stainless steel surface and allowed to dry for 1h under a ventilated biosafety cabinet protected from light.

**Decontamination of surfaces**

Decontamination followed 2 modalities: a single wipe motion from top to bottom or vigorous wiping.

- Standard application consisted in a single wipe of surfaces from top to bottom.
- Vigorous decontamination consisted in scrubbing surfaces energetically several times for a few seconds.

Decontamination was carried out using 10×10 cm wipes (Texwipe™ 3210, ITW Texwipe, Kernersville, NC, USA) moistened with 300 μL decontamination solution. Four different solutions were tested: Solution 1: 70% isopropanol (Klercide™, Ecolab, Farmham, UK); Solution 2: ethanol (91.6 mg/g) hydrogen peroxide (50.0 mg/g) (Anioxyspray™, Anios, Hellemmes, France); Solution 3: 10⁻² M sodium dodecyl sulfate:isopropanol 80:20 (home-made sterile solution) and Solution 4: 0.5% sodium hypochlorite, obtained by diluting a 3% marketed solution (Hänseler, Herisau, Switzerland) in UPW.

**Residual contamination measurement and decontamination assessment**

Residual contamination was measured by applying a liquid chromatography with tandem mass spectrometry detection method developed and validated specifically to estimate surface contamination by the tested contaminants [34–36].

Briefly, sampling was performed using a polyester swab (Texwipe™ 716, ITW Texwipe, Kernersville, NC, USA). Swabs were humidified with 100 μL of 75% IPA (50 μL/side) for wipe sampling [36], then introduced into 12-mL amber glass tubes containing 2-mL of desorption solution (10 mM acetic + 2% acetonitrile) and the 5 internal standards. The tube was then vortexed for a few seconds. The aqueous solution was analysed according to a previously published method [34,35].

**Statistics**

All experiments were repeated 6 times and were conducted by a single operator to limit inter-individual variability of the results.

Samples were considered contaminated if at least one contaminant was quantified. For a few samples in which contaminants were unquantifiable because the signal ranged between the LOD and the LOQ, the value was expanded to the LOQ.

The contamination rate was considered to be the proportion of contaminated samples. The ability of the decontamination solution to remove chemical contamination was estimated by decontamination efficiency, defined as follows [37]:

\[
\text{Eff}_q = 1 - \frac{\text{quantity after decontamination procedure}}{\text{quantity before decontamination procedure}} \quad \text{for one contaminant} \quad \text{Eq 1}
\]
Efficiency results are presented as medians [min–max], expressed in %. Non-parametric tests were used because of the number of samples (n < 30) and normality was unverifiable. The comparison of the overall efficiency (Eff_Q) of the four solutions was performed with an ANOVA on ranks according to the Kruskal-Wallis method (P < 0.05). When this analysis revealed a significant p-value, contrasts were obtained with the Conover–Iman test on ranks to detect significant differences between couples of solution. The Bonferroni correction was applied on P-values to limit interpretation bias due to repeated tests. The two decontamination modalities were compared for each solution by a non-parametric Mann-Whitney test (p < 0.05).

Statistics were performed in using XLSTAT® for Excel® (Addinsoft, Paris, France). Figures were drawn using Excel® (Microsoft, Paris, France).

Results

Standard decontamination

The highest overall efficiency was observed with sodium hypochlorite. The medians [min–max] of overall Eff_Q were 79.9% [69.3–100]; 86.5% [13–100]; 85.4% [56.5–100] and 100% [52.9–100] for solutions 1, 2, 3 and 4, respectively. The Eff_q for each antineoplastic drug by solution are summarized in Table 1.

The lowest Eff_q were observed for etoposide (69.3%), docetaxel (44.8%), etoposide (56.5%) and docetaxel (52.9%) for solutions 1, 2, 3, and 4, respectively. The highest Eff_q was 100.0%, reached for 4, 6, 9 and 14 contaminants for solutions 1, 2, 3 and 4, respectively (Fig 1). The four solutions reached very good Eff_q for pemetrexed, daunorubicin, etoposide phosphate. As well as 100% efficiency, Eff_q reached at least 90% for 2 (ganciclovir and topotecan) and 6 contaminants (ganciclovir, raltitrexed, doxorubicin, idarubicin, topotecan and vincristine) for solutions 2 and 3, respectively. Inversely, solution 4 did not reach this threshold for 3 contaminants (cyclophosphamide, ifosfamide and docetaxel).

Vigorous decontamination

Table 2 summarizes the Eff_q for each antineoplastic drug by decontamination solution. The highest overall efficiency was observed with sodium hypochlorite. The observed Eff_Q medians were 100%, 99.6%, 92.3% and 84.3% for S4, S3, S2 and S1, respectively. Residual contamination could be observed more frequently with solutions 1 and 2.

Eff_q comparison of the four solutions using the Kruskall-Wallis test revealed some significant differences for doxorubicin (S1 = 66.0%; S2 = 95.3% vs. S3 = 100%; S4 = 100%; p = 0.011), epirubicin (S1 = 74.4%; S2 = 83.2% vs. S3 = 100%; S4 = 100%; p = 0.001), ganciclovir (S1 = 84.6%; S2 = 93.6% vs. S3 = 100%; S4 = 100%; p = 0.001), irinotecan (S1 = 82.5%; S2 = 89.3% vs. S3 = 100%; S4 = 100%; p = 0.001), methotrexate (S1 = 76.4%; S2 = 86.2% vs. S4 = 97.7%; p = 0.026), raltitrexed (S1 = 94.5%; S2 = 92.0% vs. S3 = 100%; S4 = 100%; p = 0.001) and topotecan (S1 = 92.9%; S2 = 92.3% vs. S3 = 99.6%; S4 = 100%; p = 0.004). For these contaminants, the Conovar-Iman analysis revealed contrasts between couples of solutions: solutions 3 and 4 versus solutions 1 and 2. A significant difference was observed on etoposide between the four solutions (S1 = 86.3% vs. S2 = 96.6% vs. S3 = 91.2%; S4 = 100%p = 0.001). Finally, solution 4 had a greater effect than other solutions on dacarbazine (S1 = 84.3%; S2 = 93.8%; S3 = 92.5% vs. S4 = 100%; p = 0.002).
In this context, decontamination efficiency also depended on the tested contaminant (Fig 2). The lowest $\text{Eff}_q$ were observed for doxorubicin (66.0%), paclitaxel (68.7%), cytarabine (84.8% and 82.9%) for solutions 1, 2, 3, and 4, respectively. The highest $\text{Eff}_q$ (i.e. 100%) was observed on 5, 1, 11 and 13 contaminants for solutions 1, 2, 3, and 4, respectively. An $\text{Eff}_q$ of 100% was observed on etoposide for the four tested solutions. Solution 1 reached an $\text{Eff}_q \geq 90\%$ for fludarabine, raltitrexed and topotecan. For solution 2, this threshold was attained except for cytarabine, gemcitabine, methotrexate, epirubicin, docetaxel and paclitaxel. The $\text{Eff}_q$ for solution 3 was lower than 90\% for cytarabine, methotrexate and idarubicin. In the case of solution 4, this threshold was not reached for cytarabine and gemcitabine, nor for docetaxel and paclitaxel. Both cyclophosphamide and ifosfamide were decontaminated with an $\text{Eff}_q$ of 89.8 and 89.9\%, respectively.

### Comparison of decontamination modalities

After standard application of the solutions (Fig 3), a significant difference was observed for solution 4 compared to the others ($p < 0.001$) according to the Mann-Whitney test. After vigorous application, $\text{Eff}_q$ were 84.3\% [66.0–100]; 92.3\% [68.7–100]; 99.6\% [84.8–100] and 100\% [84.8–100].

---

Table 1. Efficiency of the decontamination solutions on the 23 tested antineoplastic drugs on stainless steel surfaces after standard single motion.

| $\text{Eff}_q$ | 5FU | Cytarabine | Fludarabine | Ganciclovir | Gemcitabine | Methotrexate | Pemetrexed | Raltitrexed | Busulfan | Cyclophosphamide | Ifosfamide | Dacarbazine | Daunorubicin | Doxorubicin | Epirubicin | Etoposide phosphate | Etoposide | Docetaxel | Paclitaxel | Irgo | Irinotecan | Topotecan | Vincristine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1 m | 79.1% | 73.5% | 86.1% | 83.5% | 73.6% | 85.8% | 100.0% | 86.1% |
| S1 sd | 36.1% | 37.3% | 26.8% | 27.5% | 37.4% | 23.4% | 0.0% | 27.7% |
| S2 m | 100.0% | 76.1% | 88.1% | 94.0% | 75.5% | 85.7% | 100.0% | 100.0% |
| S2 sd | 0.0% | 25.3% | 15.3% | 14.6% | 28.5% | 13.4% | 0.0% | 0.0% |
| S3 m | 100.0% | 71.5% | 81.0% | 98.4% | 71.0% | 85.4% | 100.0% | 100.0% |
| S3 sd | 0.0% | 32.4% | 31.4% | 1.5% | 39.4% | 18.7% | 0.0% | 0.0% |
| S4 m | 100.0% | 98.5% | 94.4% | 100.0% | 99.2% | 100.0% | 100.0% | 100.0% |
| S4 sd | 0.0% | 2.6% | 8.8% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% |

Efficiency Table 1. Efficiency of the decontamination solutions on the 23 tested antineoplastic drugs on stainless steel surfaces after standard single motion.
[82.9–100] for solutions 1, 2, 3 and 4, respectively (Fig 3) with a significant difference for both solutions 3 and 4 compared to solutions 1 and 2 (p < 0.001). Vigorous application significantly increased the Eff Q of solution 3 compared to the standard application (p = 0.007). This result was not noted for the other solutions.

**Discussion**

Many products have been marketed for use in compounding units to remove chemical contamination by ICADs. Despite these, contamination is still present. [2,38]. In compounding units, both containment primary and secondary engineering controls (respectively C-PEC and C-SEC) are contaminated, which means that safety measures have to be improved. As mentioned in the <USP800> monograph, the removal of chemical contaminants may be obtained
**Table 2. Efficiency of the decontamination solutions on the 23 tested antineoplastic drugs on stainless steel surfaces after vigorous decontamination.**

| Eff<sub>q</sub> | 5FU | Cyta | Fluda | Ganci | Gem | Mtx | Peme | Ralti |
|---|---|---|---|---|---|---|---|---|
| S1 | m | 100.0% | 74.9% | 90.3% | 84.6% | 76.4% | 76.4% | 100.0% | 94.5% |
| sd | 0.0% | 13.5% | 10.4% | 9.6% | 14.9% | 29.6% | 0.0% | 4.2% |
| S2 | m | 95.9% | 83.0% | 98.2% | 93.6% | 85.2% | 86.2% | 92.3% | 92.0% |
| sd | 9.1% | 11.8% | 4.1% | 6.3% | 8.8% | 8.8% | 4.9% | 4.1% |
| S3 | m | 100.0% | 84.8% | 100.0% | 100.0% | 91.5% | 87.9% | 100.0% | 100.0% |
| sd | 0.0% | 8.1% | 0.0% | 0.0% | 7.3% | 11.4% | 0.0% | 0.0% |
| S4 | m | 100.0% | 82.9% | 91.4% | 100.0% | 88.2% | 97.7% | 100.0% | 100.0% |
| sd | 0.0% | 10.7% | 13.7% | 0.0% | 7.0% | 3.5% | 0.0% | 0.0% |

The four solutions yielded the same decontamination efficiency for cytarabine, daunorubicin, vincristine and 5-fluorouracil. Oxazophosphorines were removed more efficiently, notably with solutions 2, 3 and 4. Solution 3 had better Eff<sub>q</sub> on both docetaxel and paclitaxel (Fig 2).

https://doi.org/10.1371/journal.pone.0235131.t002

by two means: deactivation or decontamination [25]. Among the solutions tested in this study, sodium hypochlorite and hydrogen peroxide can deactivate conventional antineoplastic drugs as they are good oxidisers. As the oxidation of contaminants may generate degradation compounds, these were not detected by our assay and probably persist on the surface. Moreover, such oxidants may also act on the surfaces of isolators or BSC and may degrade them over time.

The originality of this study lies in the range of drugs studied whereas in literature the majority have been limited to few markers, sometimes up to 10 contaminants in the same contamination [26]. New data is therefore accessible even as regards oxidisers that have been studied thoroughly in the past.

Our study confirms that sodium hypochlorite has good overall efficiency compared to other solutions after standard application, especially on antimetabolites, anthracyclines, topo-I and topo-II inhibitors. These results are consistent with previously published results [27,29,33]. Indeed, 0.5% sodium hypochlorite was successfully tested on stainless steel surfaces
on a miscellaneous of 10 antineoplastic drugs with an Eff$_{Q}$ of 97.5% [33]. In the the other studies, Adé et al., and Hon et al. have tested only cyclophosphamide, with an Eff$_{Q}$ of 99.74% and 96.62%, respectively. Our result observed on paclitaxel shows that 0.5% sodium hypochlorite may be efficient, as it was previously demonstrated by Lee et al [31]. In this study, the lowest effect is observed on taxanes, with a marked effect on docetaxel, which explains the difference in the Eff$_{Q}$ range comparatively to the study of Queruau-Lamerie et al.

This study also confirms that 70% isopropanol is a poor decontaminating agent, as has already been observed [33]. In a previous literature review, the Eff$_{Q}$ of 70% isopropanol on stainless steel surfaces reached a mean of 80.6%, [26] compared with 79.9% in our study. Its decontamination effect on taxanes is higher than NaOCl, probably because it is an organic solvent capable of removing these contaminants by physicochemical affinity.

Two other decontamination solutions were tested. Marketed biocide combining an oxidiser and ethanol proved to be a poor chemical decontaminant. Indeed, if a threshold of 90% is
supposed to define a decontaminant enough efficient [39], the solution 2 (admixture of EtOH/H\textsubscript{2}O\textsubscript{2}) reached such a value for only 8 contaminants. This solution was chosen because it is used in practice as a disinfectant in many compounding units. Solution 2 was effectively previously tested in a real-life study and compared to solution 3, showing a lower efficiency [40]. As the formulation of disinfectants can vary, our results should not be generalised. It is however advisable to test whether a disinfectant is a good chemical decontaminant before using it [39].

The admixture of SDS/IPA tested here was previously assessed [28,33] and tested on different drugs, demonstrating a difference in \text{Eff}_q depending on contaminant as was also observed in our study. In the study of Queruau-Lamerie et al., such solution reached an \text{Eff}_q of 87.5% on stainless steel surfaces [33], closed from our results (i.e. 85.4%) and also shown variable \text{Eff}_q depending on the contaminant. Vigorous application tended to increase the \text{Eff}_q for all solutions, but the effect was statistically significant for only solution 3. Therefore, both disinfectant solutions proved to be the worst chemical decontaminants when compared to SDS/IPA and NaOCl in this particular case. These two solutions had comparable \text{Eff}_q after vigorous application. The biggest difference between the two solutions was certainly due to the greater effect of SDS/IPA on the two taxanes, indicating the advantage of surfactant solutions in removing lipophilic and hydrophilic drugs in the same action. A significant effect of vigorous application was found only for SDS/IPA in this study, implying the importance of application modalities (i.e. the human

Fig 3. Comparison of the overall efficiency of four decontamination or deactivation solutions according to their application modalities. White boxes represent standard decontamination and striped boxes represent vigorous decontamination. The solutions compared are 70% isopropanol (IPA), an admixture of ethanol-hydrogen peroxide (91.6–50.0 mg/g), an admixture of 10 \textsuperscript{-2} M sodium dodecyl sulfate/isopropanol (80/20) and sodium hypochlorite (NaOCl). Significant differences are observed for single standard motion between NaOCl and the other solutions and for vigorous application for both NaOCl and SDS/IPA compared to the two other solutions.

https://doi.org/10.1371/journal.pone.0235131.g003
factor) in the effectiveness of the decontamination process. This seems logical as the contaminants to be removed have to be incorporated into the formed micelles and this requires a mechanical action which may indicate variability in decontamination efficacy between operators: variability in the strength and energy applied during the decontamination process. SDS/IPA solution was previously tested during two studies in real conditions [37,40]. Among the differences between these two studies, a human factor was suspected to explain the difference in the results, notably by the application modalities of the decontamination solution [26]. It is therefore important to consider the training of the operators involved in decontamination to limit this potential interindividual factor as much as possible.

The handling of ICADs necessitates both sterility [41] and safety in care facilities [21]. The <USP800> monograph distinguished two situations relative to duality in the context of sterile compounding: removing microorganisms with a cleaning or a disinfectant solution and removing chemical contaminants using a deactivation or a decontamination solution [25]. In medical wards, this problem has to be analysed in just the same way, as antimicrobial solutions are used there but their decontamination potential is not known. In a previous work, the performance of decontamination solutions was assessed according to three characteristics: overall efficiency (Eff Q), the number of tested contaminants and the risk of using a decontamination solution [39]. For routine decontamination, two solutions among those tested here have been shown to be the best decontaminants against the whole range of contaminants tested. Therefore some critical points have to be taken into account like the oxidising character of NaOCl and the risk of deposing organic residue at the end of the decontamination process. All these points have previously been discussed [39]. The last important point with regard to our results is the human factor implicated in the whole decontamination process. Indeed, this study has highlighted that decontamination modalities can condition decontamination efficacy just as in other studies that have already explored factors liable to modify it [26]. This study also underlines the importance of operator training so as to standardise decontamination and establish the most efficient procedure which takes into account the duality of handling hazardous and sterile drugs. A new pedagogical tool could be formulated to this end [42].

**Conclusion**

This study, assessing four solutions, concludes that sodium hypochlorite is the best decontaminant after standard application although an admixture of surfactant agent and isopropanol gave the same results after vigorous application on 23 contaminants. Decontamination efficiency depends on the solution used but also on application modality. An SDS admixture seems to be a good option, notably for vigorous chemical decontamination without any hazard to either materials or workers.

**Acknowledgments**

The authors thank Alexandra Tavernier, M.A. (University of Glasgow U.K.), Professeur Agrégée (France) for her assistance in correcting and editing the text.

**Author Contributions**

**Conceptualization:** Nicolas Simon, Sandrine Fleury-Souverain.

**Formal analysis:** Nicolas Simon, Sandrine Fleury-Souverain.

**Investigation:** Nicolas Simon.

**Methodology:** Nicolas Guichard, Pascal Bonnabry, Sandrine Fleury-Souverain.
Project administration: Pascal Bonnabry.

Resources: Sandrine Fleury-Souverain.

Supervision: Sandrine Fleury-Souverain.

Writing – original draft: Nicolas Simon, Nicolas Guichard, Sandrine Fleury-Souverain.

Writing – review & editing: Pascal Odou, Bertrand Decaudin, Pascal Bonnabry, Sandrine Fleury-Souverain.

References

1. Sessink PJ, Friemel NS, Anzion RB, Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health 1994; 65: 401–403. https://doi.org/10.1007/BF00383251 PMID: 8034364

2. Sessink PJ, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US Hospital pharmacies following implementation of Closed-System Drug Transfer Device. Hosp Pharm 2013; 48:204–212. https://doi.org/10.1310/hpj4803-204 PMID: 24241463

3. Hedmer M, Tinnerberg H, Axmon A, Jönnson BAG. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008; 81:899–911 https://doi.org/10.1007/s00420-007-0284-y PMID: 18066576

4. Böhländer T, Sverdel Y, Schierl R. Antineoplastic drug residues inside homes of chemotherapy patients. Int J Hyg Environ Health. 2017; 220: 757–765. https://doi.org/10.1016/j.ijheh.2017.03.005 PMID: 28372941

5. Alexander K, Northrup N, Clarke D, Lindell H, Laver T. Engineering controls in veterinary oncology: A survey of 148 ACVIM board-certified oncologists and environmental surveillance in 20 specialty hospitals. Vet Comp Oncol. 2018; 16: 385–391. https://doi.org/10.1111/vco.12039 PMID: 29446222

6. Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1:1250–1. https://doi.org/10.1016/s0140-6736(79)91939-1 PMID: 87722

7. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993; 50:455–62. PMID: 8442491

8. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Canc Nurs 1993; 16:288–95.

9. McDiamid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1998; 30:984–7.

10. Connor TH, Lawson CC, Polovich M, McDiamid M. Reproductive health risks associated with the occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med 2014; 56:901–10. https://doi.org/10.1097/JOM.0000000000000249 PMID: 25153300

11. Villarini M, Gianfredi V, Levrato S, Vannini S, Salvatori T, Moretti M. Occupational exposure to cytostatic/antineoplastic drugs and cytogenetic damage measured using the lymphocyte cytokinesis-block micronucleus assay: A systematic review of the literature and meta-analysis. Mutat Res 2016; 770:35–45. https://doi.org/10.1016/j.mrrev.2016.05.001 PMID: 27894689

12. Harrison BR. Developing guidelines for working with antineoplastic drugs. Am J Hosp Pharm 1981; 38:1686–1693. PMID: 7304620

13. Zellmer WA. Reducing occupational exposure to potential carcinogens in hospitals. Am J Hosp Pharm 1981; 38(11):1679. PMID: 7304618

14. Zimmerman PF, Larsen RK, Barkley EW, Gallelli JF. Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 1981; 38(11): 1693–1695. PMID: 7304621

15. Yodaiken RE, Bennett D. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am J Hosp Pharm 1986; 43(5):1193–1204. PMID: 3717176

16. Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. Am J Health Syst Pharm 1996; 53(14):1669–1685. https://doi.org/10.1093/ajhp/53.14.1669 PMID: 8827233

17. Martin S, Larson E. Chemotherapy-handling practices of outpatient and office-based oncology nurses. Oncol Nurs Forum 2003; 30(4):575–581. https://doi.org/10.1188/03.ONF.575-581 PMID: 12861318
18. Centers for Disease Control and Prevention. The National Institute for Occupational Safety and Health. Hazardous exposure in healthcare–Antineoplastic drugs. https://www.cdc.gov/niosh/topics/hazdrug/antineoplastic.html

19. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 2006; 63:1172–1193.

20. GERPAC-Europharm workgroup. Preparation and administration of drugs at risk for both workers and environment. 2007 http://www.euro-pharmat.com/documents/dm_de_preparation\guidedecommandationdm.pdf

21. International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007; 13:1–81. https://doi.org/10.1177/1078155207082350 PMID: 17933809

22. European parliament. Preventing occupational exposure to cytotoxic and other hazardous drugs. Available on www.europeanbiosafetynetwork.eu

23. Power LA, Coyne JW. ASHP guidelines on hazardous drugs. Am J Health-system Pharm 2018; 75: 1996–2031. https://doi.org/10.2146/ajhp180564 PMID: 30327293

24. Boiano JM, Steeg AL, Sweeney MH. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners. J Occup Environ Hyg. 2015; 12: 598–602. https://doi.org/10.1080/15459624.2015.1029610 PMID: 25897702

25. US Pharmacopeia. USP General chapter <800> Hazardous drugs–handling in healthcare settings. Available on www.usp.org

26. Simon N, Odou P, Décaudin B, Bonnabry P, Fleury-Souverain S. Efficiency of degradation or desorption methods in antineoplastic drug decontamination: a critical review. J Oncol Pharm Pract. 2019; 25: 929–946. https://doi.org/10.1177/1078155219831427 PMID: 30786823

27. Adé A, Chauchat L, Ouellette Frèves JF, Gagné S, Caron N, Bussières JF. Comparison of decontamination efficacy of cleaning solutions on a biological safety cabinet workbench contaminated by cyclophosphamide. 2017 Can J Hosp Pharm; 70: 407–414. https://doi.org/10.4212/cjhp.v70i6.1708 PMID: 29298999

28. Boßmandt A, Groeneveld S, Fischer E, Schierl R. Cleaning Efficiencies of Three Cleaning Agents on Four Different Surfaces after Contamination by Gemcitabine and 5-fluorouracil. J Occup Environ Hyg 2015; 12:384–392. https://doi.org/10.1080/15459624.2015.1009985 PMID: 25751496

29. Hon CY, Chua PP, Danyluk Q, Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract 2014; 20:210–16. https://doi.org/10.1080/1078155213497070 PMID: 23929731

30. Lé LMM, Jollivet PA, Sadou Yaye H, Rieutord A, Bellanger A, Pradeau D et al. Effectiveness of cleaning of workplace cytotoxic surface. Int Arch Occup Environ Health 2013; 86:333–41. https://doi.org/10.1007/s00420-012-0769-1 PMID: 22526087

31. Lee SG, Ambados F, Tkaczuk M, Jankewicz G. Paclitaxel exposure and its effective decontamination. J Pharm Pract Res 2009; 39:181–5.

32. Touzin K, Bussières JF, Langlois E, Lefebvre M, Métra A. Pilot Study Comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide. Ann Occup Hyg 2010; 54: 351–9. https://doi.org/10.1093/annhyg/meq004 PMID: 20118195

33. Queruau-Lamerie T, Nussbaumer S, Décaudin B, Fleury-Souverain S, Goossens JF, Bonnabry P. Evaluation of decontamination efficacy of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents. Ann Occup Hyg 2013; 57:456–69. https://doi.org/10.1093/annhyg/mes087 PMID: 23223271

34. Guichard N., Fekete S, Guillarme D, Bonnabry P, Fleury-Souverain S. Computer-assisted UHPLC-MS method development and optimization for the determination of 24 antineoplastic drugs used in hospital pharmacy. J Pharm Biomed Anal. 2019; 164: 395–401. https://doi.org/10.1016/j.jpba.2018.11.011 PMID: 30439666

35. Guichard N, Rudaz S, Bonnabry P, Fleury-Souverain S. Method development and optimization for the determination of 24 antineoplastic drugs used in hospital pharmacy. J Pharm Biomed Anal. 2019; 164: 395–401. https://doi.org/10.1016/j.jpba.2018.11.014 PMID: 30439666

36. Guichard N, Rudaz S, Bonnabry P, Fleury-Souverain S. Validation and uncertainty estimation for trace amounts determination of 25 drugs used in hospital chemotherapy compounding units. J Pharm Biomed Anal. 2019; 172: 139–148. https://doi.org/10.1016/j.jpba.2019.04.042 PMID: 31035095

37. Anastasi M, Rudaz S, Queruau-Lamerie T, Odou P, Bonnabry P, Fleury-Souverain S. Efficacy of Two Cleaning Solutions for the Decontamination of 10 Antineoplastic Agents in the Biosafety Cabinets of a Hospital Pharmacy Ann Occup Hyg 2015; 59(7):895–898. https://doi.org/10.1093/annhyg/mes031 PMID: 25979920
38. Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study. PLoS One 2016; 11:e0159052 https://doi.org/10.1371/journal.pone.0159052 PMID: 27391697

39. Simon N, Odou P, Décaudin B, Bonnabry P, Fleury-Souverain S. Chemical decontamination of hazardous drugs: a comparison of solution performances. Annals of Work Exposure Health 2020; 64: 114–124.

40. Vasseur M, Simon N, Picher C, Richeval C, Soichot M, Humbert L, et al. A decontamination process adding a tensioactive agent and isopropanol to a closed-system drug transfer device for better control of isolator contamination. A prospective, parallel study. PLoS One. 2018; 13(8):e0201335. https://doi.org/10.1371/journal.pone.0201335 PMID: 30089139

41. European Pharmacopoeia. Edition 9.8. Monograph « Parenteralia ». Strasbourg: 2019.

42. Berthod F, Bouchoud L, Grossrieder F, Falaschi L, Senhaji S, Bonnabry P. Learning good manufacturing practices in an escape room: Validation of a new pedagogical tool. J Oncol Pharm Pract 2019; https://doi.org/10.1177/1078155219875504 PMID: 31568110